Literature DB >> 34150933

Production of the Receptor-binding Domain of the Viral Spike Proteins from 2003 and 2019 SARS CoVs and the Four Common Human Coronaviruses for Serologic Assays and Inhibitor Screening.

Bruno Segovia-Chumbez1, Stephen D Graham1, Ramesh Jadi1, Aravinda M de Silva1, Lakshmanane Premkumar1.   

Abstract

The recombinant receptor-binding domain (RBD) of the viral spike protein from SARS-CoV-1 and 2 are reliable antigens for detecting viral-specific antibodies in humans. We and others have shown that the levels of RBD-binding antibodies and SARS-CoV-2 neutralizing antibodies in patients are correlated. Here, we report the expression and purification of properly folded RBD proteins from SARS and common-cold HCoVs in mammalian cells. RBD proteins were produced with cleavable tags for affinity purification from the cell culture medium and to support multiple immunoassay platforms and drug discovery efforts. Graphic abstract: High-Yield Production of Viral Spike RBDs for Diagnostics and Drug Discovery.
Copyright © 2021 The Authors; exclusive licensee Bio-protocol LLC.

Entities:  

Keywords:  Antibody; Antigen; COVID-19; Coronavirus; Drug discovery; Halo-tag; Immunoassay; Inhibitor screening; SARS-CoV; SARS-CoV-2; Spike protein

Year:  2021        PMID: 34150933      PMCID: PMC8187116          DOI: 10.21769/BioProtoc.4026

Source DB:  PubMed          Journal:  Bio Protoc        ISSN: 2331-8325


  4 in total

1.  Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine, and Pyronaridine: In Vitro Activity against SARS-CoV-2 and Potential Mechanisms.

Authors:  Ana C Puhl; Ethan J Fritch; Thomas R Lane; Longping V Tse; Boyd L Yount; Carolina Q Sacramento; Natalia Fintelman-Rodrigues; Tatyana Almeida Tavella; Fabio Trindade Maranhão Costa; Stuart Weston; James Logue; Matthew Frieman; Lakshmanane Premkumar; Kenneth H Pearce; Brett L Hurst; Carolina Horta Andrade; James A Levi; Nicole J Johnson; Samantha C Kisthardt; Frank Scholle; Thiago Moreno L Souza; Nathaniel John Moorman; Ralph S Baric; Peter B Madrid; Sean Ekins
Journal:  ACS Omega       Date:  2021-03-10

2.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.

Authors:  Alba Grifoni; Daniela Weiskopf; Sydney I Ramirez; Jose Mateus; Jennifer M Dan; Carolyn Rydyznski Moderbacher; Stephen A Rawlings; Aaron Sutherland; Lakshmanane Premkumar; Ramesh S Jadi; Daniel Marrama; Aravinda M de Silva; April Frazier; Aaron F Carlin; Jason A Greenbaum; Bjoern Peters; Florian Krammer; Davey M Smith; Shane Crotty; Alessandro Sette
Journal:  Cell       Date:  2020-05-20       Impact factor: 66.850

3.  The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients.

Authors:  Lakshmanane Premkumar; Bruno Segovia-Chumbez; Ramesh Jadi; David R Martinez; Rajendra Raut; Alena Markmann; Caleb Cornaby; Luther Bartelt; Susan Weiss; Yara Park; Caitlin E Edwards; Eric Weimer; Erin M Scherer; Nadine Rouphael; Srilatha Edupuganti; Daniela Weiskopf; Longping V Tse; Yixuan J Hou; David Margolis; Alessandro Sette; Matthew H Collins; John Schmitz; Ralph S Baric; Aravinda M de Silva
Journal:  Sci Immunol       Date:  2020-06-11

4.  Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans.

Authors:  Alessandro Sette; Daniela Weiskopf; Jose Mateus; Alba Grifoni; Alison Tarke; John Sidney; Sydney I Ramirez; Jennifer M Dan; Zoe C Burger; Stephen A Rawlings; Davey M Smith; Elizabeth Phillips; Simon Mallal; Marshall Lammers; Paul Rubiro; Lorenzo Quiambao; Aaron Sutherland; Esther Dawen Yu; Ricardo da Silva Antunes; Jason Greenbaum; April Frazier; Alena J Markmann; Lakshmanane Premkumar; Aravinda de Silva; Bjoern Peters; Shane Crotty
Journal:  Science       Date:  2020-08-04       Impact factor: 47.728

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.